In 1998, in a lab at the Feinstein Institutes for Medical Research on Long Island, a researcher named Kevin Tracey was studying sepsis when his team noticed something they couldn’t explain. Rats whose vagus nerves had been cut produced dramatically more TNF-alpha — a key inflammatory signaling molecule — than rats whose nerves were intact. Stimulating the vagus nerve, conversely, suppressed inflammation across the body.
The finding was strange enough that it took years to publish. The dominant view at the time was that the immune system was largely autonomous: white blood cells responded to molecular signals from injured tissue, with little input from the nervous system. Tracey’s lab was claiming, in effect, that a single nerve running from the brainstem to the abdomen could turn inflammation up or down like a dial. The mechanism, eventually mapped out and named the cholinergic anti-inflammatory pathway, has since been replicated in dozens of labs and is now considered foundational to a field that didn’t really exist before Tracey’s work: bioelectronic medicine.
Stimulate the vagus, dial down the inflammation. Cut the vagus, lose the brake.
A quarter-century later, the vagus nerve has become one of the most-studied and most-stimulated structures in the human body. Five different vagus nerve stimulation (VNS) devices carry FDA approval. SetPoint Medical, a company Tracey co-founded with engineer Anthony Arnold, completed a Phase 3 trial of an implantable VNS device for rheumatoid arthritis. Non-invasive devices the size of an electric razor have been cleared for migraine and cluster headache. Trials are underway for Crohn’s disease, treatment-resistant depression, stroke recovery, and post-surgical pain.
The reason the vagus nerve matters this much, and why it’s poised to keep mattering more, comes down to a single fact of anatomy: it’s plugged into almost everything.
The most connected nerve in the body
Of the twelve cranial nerves, the vagus is the longest and most extensively distributed. The name itself is the giveaway — vagus is Latin for “wandering.” It exits the skull through the jugular foramen, runs down the neck alongside the carotid artery, branches into the heart and lungs, threads through the diaphragm, and innervates most of the gastrointestinal tract down to about the splenic flexure of the colon. Branches reach the liver, the spleen, the pancreas, and the kidneys.
About 80 percent of the vagus’s roughly 100,000 fibers are afferent — they carry information to the brain rather than from it. That asymmetry matters more than it sounds. It means the vagus is, anatomically, primarily a sensing organ. The brain is constantly receiving status updates from the heart’s rhythm, the lungs’ inflation, the gut’s chemistry, and the immune system’s activation state. Stimulating the nerve doesn’t just send signals out; it modulates the entire feedback loop between brain and body.
Clinicians often describe the vagus as the captain of the parasympathetic nervous system — the “rest and digest” counterweight to the sympathetic “fight or flight” response. Slow your heart rate, dilate your gut blood vessels, settle your breathing, dampen inflammation: that’s what tonic vagal activity does. Anesthesiologists, cardiologists, and gastroenterologists have known this for decades. What was less obvious until Tracey’s work was that this same dial could be turned with electricity.
From a sepsis experiment to a paradigm shift
Tracey’s discovery — that vagus nerve stimulation suppresses systemic inflammation — landed on what until then had been a hard wall in medicine. Doctors knew the immune system had something to do with the brain (stress lowers immunity, inflammation produces depression, “sickness behavior” is real), but the wiring diagram was murky. The cholinergic anti-inflammatory pathway gave it a name and a circuit.
The mechanism, in brief: the vagus nerve releases acetylcholine onto specific receptors (alpha-7 nicotinic, abbreviated α7nAChR) on macrophages and other immune cells in the spleen. That binding event tells those cells to stop releasing TNF-alpha, IL-1, IL-6, and other inflammatory cytokines. Stimulate the vagus, dial down the inflammation. Cut the vagus, lose the brake.
The implications cascaded fast. If a single nerve could regulate systemic inflammation, then chronic inflammatory diseases — rheumatoid arthritis, inflammatory bowel disease, lupus, sepsis — might be treatable with electrical stimulation rather than (or alongside) drugs. Tracey co-founded SetPoint Medical in 2007 to commercialize that idea. The company spent the next decade-plus running animal studies, then human pilot studies, then a pivotal Phase 3 trial.
That trial, called RESET-RA, enrolled rheumatoid arthritis patients who had failed to respond to standard biologic drugs — a notoriously hard-to-treat group. Patients received an implantable device, about the size of a multivitamin, placed near the left cervical vagus nerve. The device delivered a one-minute pulse, once a day. The Phase 3 results showed clinically meaningful improvement in disease activity scores against sham control — the first real-world demonstration that a nerve-modulating implant could replace or supplement immunosuppressive drugs for an autoimmune disease.
If the FDA approves SetPoint’s device based on that data, it will be the first vagus nerve implant cleared for an inflammatory disease — and the first time the cholinergic anti-inflammatory pathway becomes an actual prescription.
What’s already approved
While the autoimmune story is still finishing, vagus nerve stimulation is already standard care for several other conditions.
Drug-resistant epilepsy, since 1997. The original Cyberonics device (Cyberonics was acquired by LivaNova in 2015) implants a pulse generator in the chest and runs a thin lead up to the left vagus nerve in the neck. It cycles on and off automatically — typically 30 seconds on, five minutes off — reducing seizure frequency by roughly 50 percent in about half of treated patients. More than 100,000 patients worldwide have received the implant.
Treatment-resistant depression, since 2005. Same hardware, different programming. Approval for this indication was contentious — coverage by Medicare and private insurers came slowly, and some payers only began routinely covering VNS for depression in the early 2020s after long-term outcome data accumulated. But the durability of the effect (patients who respond tend to keep responding for years) is striking.
Stroke rehabilitation, since 2021. The Vivistim system from MicroTransponder takes a different approach: clinicians pair short bursts of vagus stimulation with specific physical therapy movements during rehab sessions. The vagus pulse, delivered in the moment a patient is doing a difficult arm motion, appears to enhance neuroplasticity — the brain’s ability to rewire around stroke damage. Trials showed roughly two to three times the improvement in arm function compared to physical therapy alone.
Migraine and cluster headache, since 2017 and 2018. ElectroCore’s gammaCore device is non-invasive: a handheld stimulator pressed against the side of the neck for two minutes delivers a transcutaneous pulse strong enough to reach the vagus through skin and muscle. It’s available by prescription, doesn’t require surgery, and works for a substantial fraction of patients during acute attacks.
| Indication | Device | Manufacturer | FDA cleared |
|---|---|---|---|
| Drug-resistant epilepsy | VNS Therapy | LivaNova (originally Cyberonics) | 1997 |
| Treatment-resistant depression | VNS Therapy | LivaNova | 2005 |
| Migraine | gammaCore | electroCore | 2017 |
| Cluster headache | gammaCore | electroCore | 2018 |
| Stroke rehabilitation | Vivistim Paired VNS | MicroTransponder | 2021 |
These five FDA-approved indications cover four distinct mechanism families — anticonvulsant, antidepressant, neuroplastic, and analgesic — which is itself remarkable. Most drugs do one thing. Stimulating the vagus, depending on frequency, intensity, and timing, appears to do many.
Why “the dial” framing matters
The pharmacology revolution of the 20th century was, fundamentally, about chemistry: identify a target receptor, design a molecule that binds it, mass-produce the molecule. The approach worked spectacularly — antibiotics, statins, biologics, antivirals — but it has limits built into its mechanism. A pill, taken orally, distributes throughout the body. It hits its intended target, and also every other tissue that happens to express the same receptor. Side effects are the cost of doing business.
Specificity comes from anatomy, not chemistry.
Bioelectronic medicine flips the geometry. Instead of flooding the body with a molecule and hoping it finds the right target, you find a nerve that already routes to the target and modulate the signal. Specificity comes from anatomy, not chemistry. The vagus nerve is uniquely valuable in this paradigm because it routes to so many organs that need modulation — the heart, the gut, the spleen, the immune system, the brainstem itself.
What’s more, the same nerve can be tuned to produce different downstream effects depending on how it’s stimulated. Low-frequency tonic stimulation looks anti-inflammatory; high-frequency bursts look more anticonvulsant; phasic stimulation paired with behavior looks neuroplastic. Researchers are starting to think of vagal stimulation less like a single therapy and more like a programmable interface — a control surface with knobs that can be turned for different therapeutic effects.
That’s the framing that makes the field feel less like medicine and more like instrumentation.
What’s next
Three threads are worth watching.
The first is closed-loop systems — devices that don’t just stimulate on a fixed schedule but sense the body’s state and respond. A closed-loop VNS device for epilepsy would detect the electrical signature of an oncoming seizure and fire a vagal pulse to abort it; for inflammation, it would sense rising cytokine levels and modulate accordingly. The hardware is already feasible; the algorithms and biomarkers are catching up.
The second is non-invasive entry points. Auricular VNS — stimulation through electrodes placed in the outer ear, where a small auricular branch of the vagus surfaces — is being studied for everything from anxiety to gastroparesis to long COVID. If a stick-on ear device proves comparable to an implanted neck device for some indications, the population that can access vagal therapy expands by orders of magnitude.
The third is combination therapy. The most interesting near-term opportunities aren’t VNS replacing drugs but VNS used alongside them, lowering required doses, extending response durations, or rescuing patients who’ve failed pharmacology. The Vivistim paired-stimulation approach for stroke is the proof of concept: vagal stimulation as an amplifier of an existing therapy rather than a standalone treatment.
Medicine spent two centuries learning to talk to those organs through the bloodstream. It’s now learning to talk to them through the wires that were already there.
A nerve that anatomists once described as “wandering” turns out to be running specific, addressable circuits to nearly every major organ. Medicine spent two centuries learning to talk to those organs through the bloodstream. It’s now learning to talk to them through the wires that were already there.